Skip to content

Contact +44 (0) 20 7060 7474 email us

Research (R&D)

Research and Development (R&D)

In this section you will find information products, including market research, covering research and development (R&D) in global biotechnology and pharmaceutical industries, with insight into pipelines, productivity, strategies and profiles of companies in Europe, the UK, the US and Asia.

Stay up-to-date with new products added to this category »
Title Publication Date Price
Nanobiotechnology
Applications, Markets and Companies
 February 2010 £2865
Neuroprotection
Drugs, Markets and Companies
 February 2010 £2865
Cell Screening Tools, Stem Cells and Related Analytical Products for Drug/Cell Therapy R&D
Equipment, Tools, Technologies, Opportunities & WW Market Outlook
 January 2010 £1045
Multiplex Assays
Evolving Technologies, Applications and Future Directions
December 2009 £2385
The Future of Contract Research Outsourcing
Market Forecasts to 2015, Geographical Landscape and Competitive Benchmarking
 December 2009 £2230
Competitor Analysis: Neurotrophic Growth Factors
 December 2009 £350
Innovative Drug R&D in China
 October 2009 £1845
Leading Pharmaceutical Companies R&D Expenditures and Major Programs
 September 2009 £955
Bioarrays for Life Science Research, Diagnostics and Drug R&D
 August 2009 £1590
Disease Specific Test Reagents Clinical Trial Analysis
 July 2009 £635
Disease Specific Markers Clinical Trial Analysis
 July 2009 £635
Drug Eluting Stent (DES) Clinical Trial Analysis
 July 2009 £635
Dynamic Stabilization Clinical Trial Analysis
 July 2009 £635
ECG Monitoring Equipment Clinical Trial Analysis
 July 2009 £635
Dermatology Clinical Trial Analysis
 July 2009 £635
Drug Related Testing Reagents Clinical Trial Analysis
 July 2009 £635
Coronary Stent Clinical Trial Analysis
 July 2009 £635
Coronary Guidewire Clinical Trial Analysis
 July 2009 £635
Coronary Artery Bypass Graft Surgery Clinical Trial Analysis
 July 2009 £635
Embolic Protection Device Clinical Trial Analysis
 July 2009 £635
DBM Clinical Trial Analysis
 July 2009 £635
Dental Bone Graft Substitutes and Tissue Regeneration Materials Clinical Trial Analysis
 July 2009 £635
Deep Brain Stimulators Clinical Trial Analysis
 July 2009 £635
Dental Implants Clinical Trial Analysis
 July 2009 £635
Hemostats Clinical Trial Analysis
 July 2009 £635
Incontinence Devices Clinical Trial Analysis
 July 2009 £635
Implantable Cardioverter Defibrillator Clinical Trial Analysis
 July 2009 £635
Infectious Immunology Test Reagents Clinical Trial Analysis
 July 2009 £635
Infusion Systems Clinical Trial Analysis
 July 2009 £635
Instruments Clinical Trial Analysis
 July 2009 £635
Inhalers Clinical Trial Analysis
 July 2009 £635
Hydrocephalus shunts Clinical Trial Analysis
 July 2009 £635
Hormone Related Testing Reagents Clinical Trial Analysis
 July 2009 £635
Genetic Test Reagents Clinical Trial Analysis
 July 2009 £635
Gamma Camera Clinical Trial Analysis
 July 2009 £635
Glucose Monitoring Clinical Trial Analysis
 July 2009 £635
Continuous Positive Airway Pressure Devices Clinical Trial Analysis
 July 2009 £635
Hip Replacement Clinical Trial Analysis
 July 2009 £635
Event Monitoring System Clinical Trial Analysis
 July 2009 £635
Cardiovascular Surgery Clinical Trial Analysis
 July 2009 £635
Bacteriology Clinical Trial Analysis
 July 2009 £635
Artificial Disc Replacement Clinical Trial Analysis
 July 2009 £635
Bare Metal Stent Clinical Trial Analysis
 July 2009 £635
Bariatric Devices Clinical Trial Analysis
 July 2009 £635
Blood Purification Equipment Clinical Trial Analysis
 July 2009 £635
Biopsy Devices Clinical Trial Analysis
 July 2009 £635
Aortic Stent Graft Clinical Trial Analysis
 July 2009 £635
Ankle Replacement Clinical Trial Analysis
 July 2009 £635
Ablation Equipments Clinical Trial Analysis
 July 2009 £635
Clinical Trials Market - India
 July 2009 £225
Advanced Wound Management Clinical Trial Analysis
 July 2009 £635
Aesthetic Devices Clinical Trial Analysis
 July 2009 £635
Angiography Catheter Clinical Trial Analysis
 July 2009 £635
Anastomosis Device Clinical Trial Analysis
 July 2009 £635
Bone Graft Substitutes Clinical Trial Analysis
 July 2009 £635
Bronchoscopes Clinical Trial Analysis
 July 2009 £635
Insulin Delivery Clinical Trial Analysis
 July 2009 £635
Cardiovascular Prosthetic Devices Clinical Trial Analysis
 July 2009 £635
Cell Therapy Clinical Trial Analysis
 July 2009 £635
Clinical Chemistry Rapid Tests Clinical Trial Analysis
 July 2009 £635
Colonoscope - Sigmoidoscope Clinical Trial Analysis
 July 2009 £635
Collagens Clinical Trial Analysis
 July 2009 £635
Cardiovascular Pacing and ICD Leads Clinical Trial Analysis
 July 2009 £635
Cardiovascular Monitoring and Diagnostic Devices Clinical Trial Analysis
 July 2009 £635
Cardiac Assist Devices Clinical Trial Analysis
 July 2009 £635
Cardiac Ablation Devices Clinical Trial Analysis
 July 2009 £635
Cardiac Catheter Clinical Trial Analysis
 July 2009 £635
Cardiac Markers Clinical Trial Analysis
 July 2009 £635
Cardiac Rhythm Management Clinical Trial Analysis
 July 2009 £635
Computed Tomography Systems Clinical Trial Analysis
 July 2009 £635
Electrosurgical Devices Clinical Trial Analysis
 July 2009 £635
Refractive Surgery Clinical Trial Analysis
 July 2009 £635
Prosthetic Heart Valve Clinical Trial Analysis
 July 2009 £635
Polysomnography Systems Clinical Trial Analysis
 July 2009 £635
Peripheral Vascular Stent Clinical Trial Analysis
 July 2009 £635
Remote Patient Monitoring Clinical Trial Analysis
 July 2009 £635
Repair and Restorative Materials Clinical Trial Analysis
 July 2009 £635
Semi-Permeable Films Clinical Trial Analysis
 July 2009 £635
Revision Hip Replacement Clinical Trial Analysis
 July 2009 £635
Respiratory Measurement Devices Clinical Trial Analysis
 July 2009 £635
Respiratory Devices Clinical Trial Analysis
 July 2009 £635
Peripheral Vascular Devices Clinical Trial Analysis
 July 2009 £635
PTCA Baloon Clinical Trial Analysis
 July 2009 £635
Oncology Devices Clinical Trial Analysis
 July 2009 £635
Non-Invasive Blood Glucose Monitoring device Clinical Trial Analysis
 July 2009 £635
Neurostimulation Devices Clinical Trial Analysis
 July 2009 £635
Needle Free Injections Clinical Trial Analysis
 July 2009 £635
Opthalmic Lasers Clinical Trial Analysis
 July 2009 £635
Opthalmoscope Clinical Trial Analysis
 July 2009 £635
Orthopedic Accessories Clinical Trial Analysis
 July 2009 £635
Orthodontic Materials and Products Clinical Trial Analysis
 July 2009 £635
Orthobiologics Clinical Trial Analysis
 July 2009 £635
Sleep Apnea Diagnostic Systems Clinical Trial Analysis
 July 2009 £635
Soft Contact Lenses Clinical Trial Analysis
 July 2009 £635
Interbody Cages Clinical Trial Analysis
 July 2009 £635
Viscosupplementation Clinical Trial Analysis
 July 2009 £635
Virology Clinical Trial Analysis
 July 2009 £635
Ventricular Assist Devices Clinical Trial Analysis
 July 2009 £635
Women's Health Clinical Trial Analysis
 July 2009 £635
Wound Closure Devices Clinical Trial Analysis
 July 2009 £635
Clinical Trials: World Market 2009-2024
 July 2009 £1499
Intra Ocular Lens (IOL) Clinical Trial Analysis
 July 2009 £635
Inferior Vena Cava Filter Clinical Trial Analysis
 July 2009 £635
Infection Control Products Clinical Trial Analysis
 July 2009 £635
Ventilators Clinical Trial Analysis
 July 2009 £635
Urinary Catheters Clinical Trial Analysis
 July 2009 £635
Spinal Surgery Clinical Trial Analysis
 July 2009 £635
Spinal Non-Fusion Clinical Trial Analysis
 July 2009 £635
Spinal Fusion Clinical Trial Analysis
 July 2009 £635
Spinal Cord Stimulators Clinical Trial Analysis
 July 2009 £635
Tissue Heart Valve Clinical Trial Analysis
 July 2009 £635
Tissue Sealants Clinical Trial Analysis
 July 2009 £635
Ultrasound Systems Clinical Trial Analysis
 July 2009 £635
Tumour Markers Clinical Trial Analysis
 July 2009 £635
Trauma Fixation Clinical Trial Analysis
 July 2009 £635
Multiparameter Patient Monitoring Clinical Trial Analysis
 July 2009 £635
Vision Care Clinical Trial Analysis
 July 2009 £635
Mechanical Heart Valve Clinical Trial Analysis
 July 2009 £635
Metered Dose Inhalers Clinical Trial Analysis
 July 2009 £635
Mammography Equipment Clinical Trial Analysis
 July 2009 £635
Knee Replacement Clinical Trial Analysis
 July 2009 £635
Joint Reconstruction Clinical Trial Analysis
 July 2009 £635
Interventional Cardiology Clinical Trial Analysis
 July 2009 £635
Minimally Invasive Blood Glucose Monitoring device Clinical Trial Analysis
 July 2009 £635
PAREXEL's Bio/Pharma R&D Statistical Sourcebook
2009 / 2010
 June 2009 £270
Contract Research Annual Review 2009
 June 2009 £345
Nanobiotechnologies
Applications, Markets and Companies
 May 2009 £2545
Approaches to Reducing Phase II Attrition
 May 2009 £2385
Clinical Trials Market in Russia
 May 2009 £510
Managing Clinical Investigator Compensation
 May 2009 £4900
Clinical Laboratory Testing Volume 1: Reagents and Instruments
 April 2009 £2165
Key Trends in Offshoring Pharmaceutical R&D
Company strategies, emerging markets and impact on ROI
 March 2009 £2025
Glossary & Acronyms for Clinical Research Professionals
 February 2009 £12
Interleukin-1 (IL-1) and IL-1 receptor (IL-1R) Antagonists
Competitor Analysis
 February 2009 £87
Interleukin-6 (IL-6) and Receptor (IL-6R) Antagonists
Competitor Analysis
 February 2009 £87
Understanding Stem Cell Research
 January 2009 £315
Delivery Mechanisms for Large Molecule Drugs
Successes and Failures of Leading Technologies and Key Drivers for Market Success
 January 2009 £2025
Toxicology and Pharmacology
Outsourcing, History, Process and Regulation; Technical, Political and Economic Challenges
 January 2009 £995
Conducting Clinical Trials in Europe
An Insider's Analysis
 December 2008 £2385
Forecast of the Key Pipeline Devices to Impact the Medical Equipment Market by 2012
 December 2008 £2230
Cannabinoid CB1 receptor antagonists
Competitor Analysis
 November 2008 £110
Why Do Drugs Fail?
 November 2008 £995
Pipeline Insight: Orphan Diseases in Neurology Part III: Myasthenia Gravis
 November 2008 £6000
Understanding Chiral Technologies
Chiral Technology Revenues Soar to $16.03 Billion
 November 2008 £315
The Form FDA 1572
A Reference Guide for Clinical Researchers, Sponsors, and Monitors
 October 2008 £30
Pipeline and Commercial Insight: Schizophrenia - Second generation depots protect market value
 October 2008 £8000
Emerging Opportunities with Cannabinoids
 September 2008 £795
Biomarkers: The Future of Next-Generation Drug R&D
 September 2008 £1650
Implants International Limited Product Pipeline Analysis
 August 2008 £475
IRIS International, Inc. Product Pipeline Analysis
 August 2008 £475
Innocoll Technologies Ltd Product Pipeline Analysis
 August 2008 £475
FzioMed, Inc. Product Pipeline Analysis
 August 2008 £475
Inolase Ltd. Product Pipeline Analysis
 August 2008 £475
Interface Biologics, Inc. Product Pipeline Analysis
 August 2008 £475
InterGenetics Incorporated Product Pipeline Analysis
 August 2008 £475
Intelligent Medical Devices, Inc. Product Pipeline Analysis
 August 2008 £475
Foster-Miller, Inc. Product Pipeline Analysis
 August 2008 £475
Innovent Medical Solutions, Ltd. Product Pipeline Analysis
 August 2008 £475
GRANT Life Sciences, Inc. Product Pipeline Analysis
 August 2008 £475
Hansen Medical, Inc. Product Pipeline Analysis
 August 2008 £475
HeartWare Limited Product Pipeline Analysis
 August 2008 £475
Hologic, Inc. Product Pipeline Analysis
 August 2008 £475
IMEXCO General Ltd. Product Pipeline Analysis
 August 2008 £475
Hai Kang Life Corporation Limited Product Pipeline Analysis
 August 2008 £475
Greatbatch, Inc. Product Pipeline Analysis
 August 2008 £475
Gen-Probe Incorporated Product Pipeline Analysis
 August 2008 £475
Gene Express, Inc. Product Pipeline Analysis
 August 2008 £475
Genzyme Corporation Product Pipeline Analysis
 August 2008 £475
Glycominds Ltd. Product Pipeline Analysis
 August 2008 £475
Interleukin Genetics Incorporated Product Pipeline Analysis
 August 2008 £475
Jarvik Heart, Inc. Product Pipeline Analysis
 August 2008 £475
OccuLogix, Inc. Product Pipeline Analysis
 August 2008 £475
Novo Nordisk AS Product Pipeline Analysis
 August 2008 £475
Omrix Biopharmaceuticals, Inc. Product Pipeline Analysis
 August 2008 £475
Onconome, Inc. Product Pipeline Analysis
 August 2008 £475
Optiscan Imaging Limited Product Pipeline Analysis
 August 2008 £475
Northstar Neuroscience, Inc. Product Pipeline Analysis
 August 2008 £475
Non-Invasive Monitoring Systems, Inc. Product Pipeline Analysis
 August 2008 £475
NMT Medical, Inc. Product Pipeline Analysis
 August 2008 £475
Nerites Corporation Product Pipeline Analysis
 August 2008 £475
Nexa Orthopedics, Inc. Product Pipeline Analysis
 August 2008 £475
Nicast LTD Product Pipeline Analysis
 August 2008 £475
OraSure Technologies, Inc. Product Pipeline Analysis
 August 2008 £475
Orion Genomics Product Pipeline Analysis
 August 2008 £475
Philips Medical Systems Product Pipeline Analysis
 August 2008 £475
Perceptronix Medical Inc. Product Pipeline Analysis
 August 2008 £475
Protein Polymer Technologies, Inc. Product Pipeline Analysis
 August 2008 £475
QUASAR, Inc. Product Pipeline Analysis
 August 2008 £475
Qiagen N.V. Product Pipeline Analysis
 August 2008 £475
Paieon Inc. Product Pipeline Analysis
 August 2008 £475
OxyBand Technologies, Inc. Product Pipeline Analysis
 August 2008 £475
Ornim, Inc. Product Pipeline Analysis
 August 2008 £475
Ortec International, Inc. Product Pipeline Analysis
 August 2008 £475
Orthovita, Inc. Product Pipeline Analysis
 August 2008 £475
Osmetech plc Product Pipeline Analysis
 August 2008 £475
NIDEK CO., LTD. Product Pipeline Analysis
 August 2008 £475
Miraculins Inc. Product Pipeline Analysis
 August 2008 £475
LeMaitre Vascular, Inc. Product Pipeline Analysis
 August 2008 £475
Kyphon Inc. Product Pipeline Analysis
 August 2008 £475
Levitronix LLC Product Pipeline Analysis
 August 2008 £475
Lifecore Biomedical, Inc. Product Pipeline Analysis
 August 2008 £475
LightLab Imaging, Inc. Product Pipeline Analysis
 August 2008 £475
Kuros Biosurgery AG Product Pipeline Analysis
 August 2008 £475
Kiscomedica Product Pipeline Analysis
 August 2008 £475
FUJIFILM Medical Systems USA, Inc. Product Pipeline Analysis
 August 2008 £475
Jemo Spine, LLC. Product Pipeline Analysis
 August 2008 £475
JenaValve Technology GmbH Product Pipeline Analysis
 August 2008 £475
Kensey Nash Corporation Product Pipeline Analysis
 August 2008 £475
Lombard Medical Technologies PLC Product Pipeline Analysis
 August 2008 £475
MC3, Inc. Product Pipeline Analysis
 August 2008 £475
Micrus Endovascular Corporation Product Pipeline Analysis
 August 2008 £475
MicroMed Cardiovascular, Inc. Product Pipeline Analysis
 August 2008 £475
Milagen, Inc. Product Pipeline Analysis
 August 2008 £475
Mindray Medical International Limited Product Pipeline Analysis
 August 2008 £475
Minos Medical Inc. Product Pipeline Analysis
 August 2008 £475
Merit Medical Systems, Inc. Product Pipeline Analysis
 August 2008 £475
Medtronic, Inc. Product Pipeline Analysis
 August 2008 £475
MND DIAGNOSTIC LTD. Product Pipeline Analysis
 August 2008 £475
Malaysian Bio-Diagnostics Research Sdn Bhd Product Pipeline Analysis
 August 2008 £475
MedWaves Incorporated Product Pipeline Analysis
 August 2008 £475
Medlogics Device Corporation Product Pipeline Analysis
 August 2008 £475
Ivoclar Vivadent AG Product Pipeline Analysis
 August 2008 £475
DePuy, Inc. Product Pipeline Analysis
 August 2008 £475
CryoLife, Inc. Product Pipeline Analysis
 August 2008 £475
Cyberkinetics Neurotechnology Systems, Inc. Product Pipeline Analysis
 August 2008 £475
Bioheart, Inc. Product Pipeline Analysis
 August 2008 £475
BioTex, Inc. Product Pipeline Analysis
 August 2008 £475
Correlogic Systems, Inc. Product Pipeline Analysis
 August 2008 £475
Corin Group PLC Product Pipeline Analysis
 August 2008 £475
CorNova, Inc. Product Pipeline Analysis
 August 2008 £475
Cordis Corporation Product Pipeline Analysis
 August 2008 £475
Corgenix, Inc. Product Pipeline Analysis
 August 2008 £475
BioCure, Inc. Product Pipeline Analysis
 August 2008 £475
Bio-Spine Corp. Product Pipeline Analysis
 August 2008 £475
Bausch & Lomb Incorporated Product Pipeline Analysis
 August 2008 £475
BSD Medical Corporation Product Pipeline Analysis
 August 2008 £475
BG Medicine, Inc. Product Pipeline Analysis
 August 2008 £475
8sens.biognostic GmbH Product Pipeline Analysis
 August 2008 £475
Rafael Medical Technologies, Inc. Product Pipeline Analysis
 August 2008 £475
Berlin Heart GmbH Product Pipeline Analysis
 August 2008 £475
Beckman Coulter, Inc. Product Pipeline Analysis
 August 2008 £475
Bayer HealthCare AG Product Pipeline Analysis
 August 2008 £475
CorAssist Cardiovascular Ltd. Product Pipeline Analysis
 August 2008 £475
Cook Medical Product Pipeline Analysis
 August 2008 £475
C.R. Bard, Inc. Product Pipeline Analysis
 August 2008 £475
Cardima, Inc. Product Pipeline Analysis
 August 2008 £475
Cardiogenesis Corporation Product Pipeline Analysis
 August 2008 £475
Carestream Health, Inc. Kodak Health Group Product Pipeline Analysis
 August 2008 £475
Boston Scientific Corporation Product Pipeline Analysis
 August 2008 £475
Biotest Diagnostics Corporation Product Pipeline Analysis
 August 2008 £475
Bioring SA Product Pipeline Analysis
 August 2008 £475
Bioscan Technologies Inc. Product Pipeline Analysis
 August 2008 £475
Biosite Incorporated Product Pipeline Analysis
 August 2008 £475
Carl Zeiss Meditec AG Product Pipeline Analysis
 August 2008 £475
CathRx Ltd Product Pipeline Analysis
 August 2008 £475
Collagen Matrix, Inc. Product Pipeline Analysis
 August 2008 £475
CompuMed, Inc. Product Pipeline Analysis
 August 2008 £475
Confluent Surgical Inc. Product Pipeline Analysis
 August 2008 £475
Clinical Cell Culture Limited Product Pipeline Analysis
 August 2008 £475
China Sky One Medical, Inc. Product Pipeline Analysis
 August 2008 £475
CellTran Limited Product Pipeline Analysis
 August 2008 £475
Chembio Diagnostic Systems, Inc. Product Pipeline Analysis
 August 2008 £475
China Medical Technologies, Inc. Product Pipeline Analysis
 August 2008 £475
Ayanda Biosystems S.A. Product Pipeline Analysis
 August 2008 £475
AutoGenomics, Inc. Product Pipeline Analysis
 August 2008 £475
CytoCore, Inc. Product Pipeline Analysis
 August 2008 £475
DNAPrint Genomics, Inc. Product Pipeline Analysis
 August 2008 £475
Biomet, Inc. Product Pipeline Analysis
 August 2008 £475
Debiotech S.A. Product Pipeline Analysis
 August 2008 £475
A&G Pharmaceutical, Inc. Product Pipeline Analysis
 August 2008 £475
A-Spine Holding Group Corp. Product Pipeline Analysis
 August 2008 £475
Abbott Diagnostics Product Pipeline Analysis
 August 2008 £475
AOI Medical, Inc. Product Pipeline Analysis
 August 2008 £475
AI Medical Devices Inc. Product Pipeline Analysis
 August 2008 £475
DiaGenic ASA Product Pipeline Analysis
 August 2008 £475
Disc Motion Technologies Product Pipeline Analysis
 August 2008 £475
Epigenomics AG Product Pipeline Analysis
 August 2008 £475
Epinex Diagnostics Incorporated Product Pipeline Analysis
 August 2008 £475
Eurocor GmbH Product Pipeline Analysis
 August 2008 £475
Endovasc, Inc. Product Pipeline Analysis
 August 2008 £475
Edwards Lifesciences Corporation Product Pipeline Analysis
 August 2008 £475
Doxa AB Product Pipeline Analysis
 August 2008 £475
ENTrigue Surgical, Inc. Product Pipeline Analysis
 August 2008 £475
Eden Spine, LLC Product Pipeline Analysis
 August 2008 £475
Access Bio, Inc. Product Pipeline Analysis
 August 2008 £475
AccuTech, LLC Product Pipeline Analysis
 August 2008 £475
Arrow International, Inc. Product Pipeline Analysis
 August 2008 £475
Aptus Endosystems, Inc. Product Pipeline Analysis
 August 2008 £475
Angiotech Pharmaceuticals, Inc. Product Pipeline Analysis
 August 2008 £475
Analogic Corporation Product Pipeline Analysis
 August 2008 £475
Arthro Kinetics plc Product Pipeline Analysis
 August 2008 £475
Artimplant AB Product Pipeline Analysis
 August 2008 £475
AtriCure, Inc. Product Pipeline Analysis
 August 2008 £475
Ash Access Technology, Inc. Product Pipeline Analysis
 August 2008 £475
Asclepion Laser Technologies GmbH Product Pipeline Analysis
 August 2008 £475
Amic AB Product Pipeline Analysis
 August 2008 £475
Alphatec Holdings, Inc. Product Pipeline Analysis
 August 2008 £475
Advanced Medical Optics, Inc. Product Pipeline Analysis
 August 2008 £475
AdnaGen AG Product Pipeline Analysis
 August 2008 £475
Active Implants Corporation Product Pipeline Analysis
 August 2008 £475
Advanced Refractive Technologies, Inc. Product Pipeline Analysis
 August 2008 £475
Advanced Surgical Design & Manufacture Limited Product Pipeline Analysis
 August 2008 £475
Align Technology, Inc. Product Pipeline Analysis
 August 2008 £475
Alfa Scientific Designs, Inc. Product Pipeline Analysis
 August 2008 £475
Alcon, Inc. Product Pipeline Analysis
 August 2008 £475
ExonHit Therapeutics SA Product Pipeline Analysis
 August 2008 £475
Theken Spine, LLC Product Pipeline Analysis
 August 2008 £475
AGA Medical Corporation Product Pipeline Analysis
 August 2008 £475
pSivida Limited Product Pipeline Analysis
 August 2008 £475
ev3 Inc. Product Pipeline Analysis
 August 2008 £475
eXagen DIAGNOSTICS, Inc. Product Pipeline Analysis
 August 2008 £475
BioTech One Inc Product Pipeline Analysis
 August 2008 £475
Biocompatibles International plc Product Pipeline Analysis
 August 2008 £475
Cepheid Product Pipeline Analysis
 August 2008 £475
CSMG Technologies, Inc. Product Pipeline Analysis
 August 2008 £475
BodyTel Scientific Inc. Product Pipeline Analysis
 August 2008 £475
diaDexus, Inc. Product Pipeline Analysis
 August 2008 £475
aap Implantate AG Product Pipeline Analysis
 August 2008 £475
Veryan Medical Product Pipeline Analysis
 August 2008 £475
VentriPoint, Inc. Product Pipeline Analysis
 August 2008 £475
Ventana Medical Systems, Inc. Product Pipeline Analysis
 August 2008 £475
Visual Pathways, Inc. Product Pipeline Analysis
 August 2008 £475
XTENT, Inc. Product Pipeline Analysis
 August 2008 £475
Zimmer Holdings, Inc. Product Pipeline Analysis
 August 2008 £475
ZONARE Medical Systems, Inc. Product Pipeline Analysis
 August 2008 £475
Xhale Diagnostics, Inc. Product Pipeline Analysis
 August 2008 £475
CooperVision, Inc. Product Pipeline Analysis
 August 2008 £475
Diazyme Laboratories Product Pipeline Analysis
 August 2008 £475
Reliant Technologies Inc. Product Pipeline Analysis
 August 2008 £475
Pioneer Surgical Technology, Inc. Product Pipeline Analysis
 August 2008 £475
MAKO Surgical Corp. Product Pipeline Analysis
 August 2008 £475
Scient'x USA Product Pipeline Analysis
 August 2008 £255
Siemens AG Product Pipeline Analysis
 August 2008 £475
Ranier Technology Limited Product Pipeline Analysis
 August 2008 £475
Translumina GmbH Product Pipeline Analysis
 August 2008 £475
Sorin S.p.A. Product Pipeline Analysis
 August 2008 £475
LifeAssays AB Product Pipeline Analysis
 August 2008 £475
LDR Holding Corporation Product Pipeline Analysis
 August 2008 £475
Gambro AB Product Pipeline Analysis
 August 2008 £475
GUIDED THERAPEUTICS, INC. Product Pipeline Analysis
 August 2008 £475
ECI Biotech Inc. Product Pipeline Analysis
 August 2008 £475
Globus Medical, Inc. Product Pipeline Analysis
 August 2008 £475
Inion Oy Product Pipeline Analysis
 August 2008 £475
KYOCERA Corporation Product Pipeline Analysis
 August 2008 £475
Insight MRI Product Pipeline Analysis
 August 2008 £475
Innova Biotechnology Co., Ltd. Product Pipeline Analysis
 August 2008 £475
VERTEBRON Inc. Product Pipeline Analysis
 August 2008 £475
BIOTRONIK GmbH & Co. KG Product Pipeline Analysis
 August 2008 £475
Spine Smith, LP Product Pipeline Analysis
 August 2008 £475
Smith & Nephew Plc Product Pipeline Analysis
 August 2008 £475
Small Bone Innovations, Inc. Product Pipeline Analysis
 August 2008 £475
Sientra, Inc. Product Pipeline Analysis
 August 2008 £475
SpineCraft, Inc. Product Pipeline Analysis
 August 2008 £475
Spire Corporation Product Pipeline Analysis
 August 2008 £475
SutureAid Product Pipeline Analysis
 August 2008 £475
Stryker Corporation Product Pipeline Analysis
 August 2008 £475
Straumann Holding AG Product Pipeline Analysis
 August 2008 £475
St. Jude Medical Inc. Product Pipeline Analysis
 August 2008 £475
Siemens Medical Solutions Product Pipeline Analysis
 August 2008 £475
Shina Systems Ltd. Product Pipeline Analysis
 August 2008 £475
SEQUENOM, Inc. Product Pipeline Analysis
 August 2008 £475
Roche Diagnostics Limited Product Pipeline Analysis
 August 2008 £475
Regentis Biomaterials Ltd. Product Pipeline Analysis
 August 2008 £475
Raymedica, LLC Product Pipeline Analysis
 August 2008 £475
U.S. Spinal Technologies, LLC Product Pipeline Analysis
 August 2008 £475
STAAR Surgical Company Product Pipeline Analysis
 August 2008 £475
Serica Technologies, Inc. Product Pipeline Analysis
 August 2008 £475
Sequella, Inc. Product Pipeline Analysis
 August 2008 £475
SensiGen, LLC. Product Pipeline Analysis
 August 2008 £475
Sahajanand Medical technologies Pvt. Ltd. Product Pipeline Analysis
 August 2008 £475
Symphony Medical, Inc. Product Pipeline Analysis
 August 2008 £475
SQI Diagnostics Inc. Product Pipeline Analysis
 August 2008 £475
Tissue Repair Company Product Pipeline Analysis
 August 2008 £475
Third Wave Technologies, Inc. Product Pipeline Analysis
 August 2008 £475
Target Discovery, Inc. Product Pipeline Analysis
 August 2008 £475
Targeted Diagnostics & Therapeutics, Inc. Product Pipeline Analysis
 August 2008 £475
Terumo Corporation Product Pipeline Analysis
 August 2008 £475
Tepha, Inc. Product Pipeline Analysis
 August 2008 £475
The Spectranetics Corporation Product Pipeline Analysis
 August 2008 £475
Thoratec Corporation Product Pipeline Analysis
 August 2008 £475
Toshiba America Medical Systems, Inc. Product Pipeline Analysis
 August 2008 £475
SyntheMed, Inc. Product Pipeline Analysis
 August 2008 £475
TEKIA, INC. Product Pipeline Analysis
 August 2008 £475
ThermoGenesis Corp. Product Pipeline Analysis
 August 2008 £475
Synovis Life Technologies, Inc. Product Pipeline Analysis
 August 2008 £475
The Magstim Company Limited Product Pipeline Analysis
 August 2008 £475
Clinical Trial Excellence
Toolkit for Winning Investigators in a Competitive Marketplace
 August 2008 £2710
International Research in Healthcare
July 2008 £29.95
Global Clinical Trial Business Report & Analysis 2008-2018
 July 2008 £1499
Antibiotic R&D
Resolving the Paradox between Unmet Medical Need and Commercial Incentive
 July 2008 £2385
Streamlining Clinical Trials
 July 2008 £4900
Clinical trials in Poland 2008
Development forecasts for 2008-2010
 June 2008 £1375
Pipeline Insight: Non-insulin antidiabetics Incretin mimetics leaders in a diverse pipeline
 May 2008 £6000
Innovative Clinical Trial Design and Management
Trends, Success Stories and Impact upon R&D Budgets
 May 2008 £1995
Clinical trials in Russia 2008
Russia compared to other countries
 April 2008 £1240
A Quick Guide to Clinical Trials
For people who may not know it all
 April 2008 £60
Investigator-Initiated Trials
Building Superior IIT Capabilities
 March 2008 £4900
Contract Research and Manufacturing Services
India (CRAMS)
 March 2008 £600
Litt's Drug Eruption
Reference Manual Including Drug Interactions
 March 2008 £145
Kidneys and Genito-Urinary System - Hyperphosphatemia Drug Pipeline Report
 February 2008 £635
Kidneys and Genito-Urinary System - Kidney Stones Drug Pipeline Report
 February 2008 £635
Kidneys and Genito-Urinary System - Erectile Dysfunction Drug Pipeline Report
 February 2008 £635
Kidneys and Genito-Urinary System - Diabetic Nephropathy Drug Pipeline Report
 February 2008 £635
Kidneys and Genito-Urinary System - Overactive Bladder Drug Pipeline Report
 February 2008 £635
Kidney Cancer Drug Pipeline Report
 February 2008 £950
Kidneys and Genito-Urinary System - Benign Prostatic Hyperplasia Drug Pipeline Report
 February 2008 £635
Metabolic Endocrinology - Diabetic Neuropathy Drug Pipeline Report
 February 2008 £635
Metabolic Endocrinology - Hypercalcemia Drug Pipeline Report
 February 2008 £635
Infections - Viral Infections Drug Pipeline Report
 February 2008 £635
Metabolic Endocrinology - Cachexia Drug Pipeline Report
 February 2008 £635
Metabolic Endocrinology - Hypocalcemia Drug Pipeline Report
 February 2008 £635
Liver Cancer Drug Pipeline Report
 February 2008 £635
Melanoma or Skin Cancer Drug Pipeline Report
 February 2008 £950
Kidneys and Genito-Urinary System - Urinary Incontinence Drug Pipeline Report
 February 2008 £635
Infections - Bacterial Infections Drug Pipeline Report
 February 2008 £950
Infections - Fungal Infections or Candidiasis Drug Pipeline Report
 February 2008 £950
Infections - Helminthic Infestations Drug Pipeline Report
 February 2008 £635
Infections - Fever Drug Pipeline Report
 February 2008 £635
Infections - Ear Infections Drug Pipeline Report
 February 2008 £635
Metabolic Endocrinology - Hypogonadism Drug Pipeline Report
 February 2008 £635
Infections - AIDS HIV Drug Pipeline Report
 February 2008 £950
Infections - Hepatitis B Drug Pipeline Report
 February 2008 £950
Infections - Hepatitis C Drug Pipeline Report
 February 2008 £950
Infections - Staphylococcal Infections Drug Pipeline Report
 February 2008 £950
Infections - Tuberculosis Drug Pipeline Report
 February 2008 £635
Infections - Pneumonia Drug Pipeline Report
 February 2008 £950
Infections - Malaria Drug Pipeline Report
 February 2008 £635
Infections - Herpes Simplex Virus Infection Drug Pipeline Report
 February 2008 £635
Infections - Influenza Drug Pipeline Report
 February 2008 £950
Infections - Urinary Tract Infections Drug Pipeline Report
 February 2008 £635
Musculo-Skeletal-Disorders - Gout Drug Pipeline Report
 February 2008 £635
Respiratory and Pulmonary System - Cystic Fibrosis Drug Pipeline Report
 February 2008 £635
Respiratory and Pulmonary System - Nasal congestion Drug Pipeline Report
 February 2008 £635
Substance Abuse - Alcoholism Drug Pipeline Report
 February 2008 £635
Respiratory and Pulmonary System - Cough Drug Pipeline Report
 February 2008 £635
Respiratory and Pulmonary System - Chronic Obstructive Pulmonary Disease Drug Pipeline Report
 February 2008 £950
Respiratory and Pulmonary System - Bronchitis Drug Pipeline Report
 February 2008 £635
Respiratory and Pulmonary System - Bronchospasm Drug Pipeline Report
 February 2008 £635
Substance Abuse - Poisoning Drug Pipeline Report
 February 2008 £635
Substance Abuse - Smoking Cessation Drug Pipeline Report
 February 2008 £635
Women's Health - Menopausal Symptoms Drug Pipeline Report
 February 2008 £635
Women's Health - Vaginal Infections Drug Pipeline Report
 February 2008 £635
Metabolic Endocrinology - Obesity Drug Pipeline Report
 February 2008 £950
Women's Health - Infertility Drug Pipeline Report
 February 2008 £635
Women's Health - Female Sexual Dysfunction Drug Pipeline Report
 February 2008 £635
Women's Health - Contraception Drug Pipeline Report
 February 2008 £635
Women's Health - Endometriosis Drug Pipeline Report
 February 2008 £635
Respiratory and Pulmonary System - Asthma Drug Pipeline Report
 February 2008 £950
Substance Abuse - Antidote Drug Pipeline Report
 February 2008 £635
Musculo-Skeletal-Disorders - Muscle Pain Drug Pipeline Report
 February 2008 £635
Non-Hodgkin Lymphoma Drug Pipeline Report
 February 2008 £950
Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Drug Pipeline Report
 February 2008 £950
Multiple Myeloma Drug Pipeline Report
 February 2008 £950
Metabolic Endocrinology - Vitamin Deficiency Drug Pipeline Report
 February 2008 £635
Metabolic Endocrinology - Type I Diabetes Drug Pipeline Report
 February 2008 £635
Prostate Cancer Drug Pipeline Report
 February 2008 £950
Metabolic Endocrinology - Type II Diabetes Drug Pipeline Report
 February 2008 £950
Ophthalmology and Optometry - Conjunctivitis Drug Pipeline Report
 February 2008 £635
Musculo-Skeletal-Disorders - Osteoarthritis Drug Pipeline Report
 February 2008 £950
Ophthalmology and Optometry - Macular Degeneration Drug Pipeline Report
 February 2008 £950
Ophthalmology and Optometry - Ocular Inflammation Drug Pipeline Report
 February 2008 £635
Pancreatic Cancer Drug Pipeline Report
 February 2008 £950
Ophthalmology and Optometry - Glaucoma Drug Pipeline Report
 February 2008 £950
Ovarian Cancer Drug Pipeline Report
 February 2008 £950
Ophthalmology and Optometry - Dry Eyes Drug Pipeline Report
 February 2008 £635
Ophthalmology and Optometry - Eye Infections Drug Pipeline Report
 February 2008 £635
Targanta Therapeutics Corp. -Detailed Product Pipeline
 February 2008 £240
Targeted Genetics Corp -Detailed Product Pipeline
 February 2008 £240
Taro Pharmaceutical Industries Ltd -Detailed Product Pipeline
 February 2008 £240
Targacept Inc -Detailed Product Pipeline
 February 2008 £240
TapImmune, Inc. -Detailed Product Pipeline
 February 2008 £240
Telik Inc -Detailed Product Pipeline
 February 2008 £240
Synthetic Blood International Inc -Detailed Product Pipeline
 February 2008 £240
Synvista Therapeutics, Inc. -Detailed Product Pipeline
 February 2008 £240
Tapestry Pharmaceuticals, Inc. -Detailed Product Pipeline
 February 2008 £240
TorreyPines Therapeutics, Inc. -Detailed Product Pipeline
 February 2008 £240
Threshold Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Titan Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
SyntheMed Inc -Detailed Product Pipeline
 February 2008 £240
Theravance Inc -Detailed Product Pipeline
 February 2008 £240
The Quigley Corporation -Detailed Product Pipeline
 February 2008 £240
Tetragenex Pharmaceuticals, Inc. -Detailed Product Pipeline
 February 2008 £240
Teva Pharmaceutical Industries Ltd -Detailed Product Pipeline
 February 2008 £240
The Medicines Company -Detailed Product Pipeline
 February 2008 £240
Tercica Inc -Detailed Product Pipeline
 February 2008 £240
Solbec Pharmaceuticals Ltd -Detailed Product Pipeline
 February 2008 £240
Spherix Incorporated -Detailed Product Pipeline
 February 2008 £240
Starpharma Holdings Ltd -Detailed Product Pipeline
 February 2008 £240
Stellar Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Spectrum Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Sonus Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Smith & Nephew Plc -Detailed Product Pipeline
 February 2008 £240
Transition Therapeutics Inc. -Detailed Product Pipeline
 February 2008 £240
Somaxon Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Stem Cell Innovations Inc -Detailed Product Pipeline
 February 2008 £240
StemCells Inc -Detailed Product Pipeline
 February 2008 £240
Sygnis Pharma AG -Detailed Product Pipeline
 February 2008 £240
Symbollon Pharmaceuticals Inc CL A -Detailed Product Pipeline
 February 2008 £240
Synovics Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Swiss Medica Inc -Detailed Product Pipeline
 February 2008 £240
SuperGen Inc -Detailed Product Pipeline
 February 2008 £240
Stryker Corp -Detailed Product Pipeline
 February 2008 £240
Sucampo Pharmaceuticals, Inc. -Detailed Product Pipeline
 February 2008 £240
Sunesis Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Synta Pharmaceuticals Corp. -Detailed Product Pipeline
 February 2008 £240
Vion Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Women First Healthcare Inc. -Detailed Product Pipeline
 February 2008 £240
Wyeth -Detailed Product Pipeline
 February 2008 £240
XELR8, Inc. -Detailed Product Pipeline
 February 2008 £240
Watson Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Warner Chilcott Limited -Detailed Product Pipeline
 February 2008 £240
Vital Living Inc -Detailed Product Pipeline
 February 2008 £240
Vyrex Corp -Detailed Product Pipeline
 February 2008 £240
Vyteris Holdings (Nevada) Inc -Detailed Product Pipeline
 February 2008 £240
XOMA Ltd -Detailed Product Pipeline
 February 2008 £240
XTL Biopharmaceuticals Ltd -Detailed Product Pipeline
 February 2008 £240
ZymoGenetics Inc -Detailed Product Pipeline
 February 2008 £240
deCODE genetics Inc -Detailed Product Pipeline
 February 2008 £240
SkyePharma Plc -Detailed Product Pipeline
 February 2008 £240
Zila Inc -Detailed Product Pipeline
 February 2008 £240
ZIOPHARM Oncology Inc -Detailed Product Pipeline
 February 2008 £240
Xechem International Inc. -Detailed Product Pipeline
 February 2008 £240
Xenoport Inc -Detailed Product Pipeline
 February 2008 £240
YM BioSciences Inc -Detailed Product Pipeline
 February 2008 £240
Viropharma Inc -Detailed Product Pipeline
 February 2008 £240
Viral Genetics Inc -Detailed Product Pipeline
 February 2008 £240
Urigen Pharmaceuticals, Inc. -Detailed Product Pipeline
 February 2008 £240
VIA Pharmaceuticals, Inc. -Detailed Product Pipeline
 February 2008 £240
VIVUS Inc -Detailed Product Pipeline
 February 2008 £240
United Therapeutics Corporation -Detailed Product Pipeline
 February 2008 £240
Unigene Laboratories Inc -Detailed Product Pipeline
 February 2008 £240
Trubion Pharmaceuticals Inc. -Detailed Product Pipeline
 February 2008 £240
ULURU Inc -Detailed Product Pipeline
 February 2008 £240
USANA Health Sciences Inc -Detailed Product Pipeline
 February 2008 £240
Valeant Pharmaceuticals International -Detailed Product Pipeline
 February 2008 £240
Vanda Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Vical Inc -Detailed Product Pipeline
 February 2008 £240
VioQuest Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Viragen Inc -Detailed Product Pipeline
 February 2008 £240
ViRexx Medical Corp -Detailed Product Pipeline
 February 2008 £240
Vertex Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Vaso Active Pharmaceuticals -Detailed Product Pipeline
 February 2008 £240
Vasogen Inc -Detailed Product Pipeline
 February 2008 £240
Vernalis Plc ADR -Detailed Product Pipeline
 February 2008 £240
Trimeris Inc -Detailed Product Pipeline
 February 2008 £240
Replidyne Inc -Detailed Product Pipeline
 February 2008 £240
EntreMed Inc -Detailed Product Pipeline
 February 2008 £240
Enhance Biotech Inc -Detailed Product Pipeline
 February 2008 £240
Enzo Biochem Inc -Detailed Product Pipeline
 February 2008 £240
Enzon Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
EpiCept Corp -Detailed Product Pipeline
 February 2008 £240
Endovasc Inc (NV) -Detailed Product Pipeline
 February 2008 £240
Endo Pharmaceuticals Holdings Inc -Detailed Product Pipeline
 February 2008 £240
Elite Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Emergent BioSolutions Inc -Detailed Product Pipeline
 February 2008 £240
Emisphere Technologies Inc -Detailed Product Pipeline
 February 2008 £240
Encysive Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Epigenomics AG -Detailed Product Pipeline
 February 2008 £240
Eqitx Ltd -Detailed Product Pipeline
 February 2008 £240
Forticell Bioscience, Inc. -Detailed Product Pipeline
 February 2008 £240
Forest Laboratories Inc -Detailed Product Pipeline
 February 2008 £240
GPC Biotech AG -Detailed Product Pipeline
 February 2008 £240
GTC Biotherapeutics Inc -Detailed Product Pipeline
 February 2008 £240
GTX INC -Detailed Product Pipeline
 February 2008 £240
Forbes Medi -Tech Inc -Detailed Product Pipeline
 February 2008 £240
Flamel Technologies SA ADS -Detailed Product Pipeline
 February 2008 £240
Eugene Science Inc -Detailed Product Pipeline
 February 2008 £240
Eurand N.V. -Detailed Product Pipeline
 February 2008 £240
Exelixis Inc -Detailed Product Pipeline
 February 2008 £240
Favrille Inc -Detailed Product Pipeline
 February 2008 £240
Eli Lilly & Co -Detailed Product Pipeline
 February 2008 £240
Elan Corp Plc -Detailed Product Pipeline
 February 2008 £240
DUSA Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
DURECT Corporation -Detailed Product Pipeline
 February 2008 £240
Dendreon Corp -Detailed Product Pipeline
 February 2008 £240
Depomed Inc -Detailed Product Pipeline
 February 2008 £240
Derma Sciences Inc -Detailed Product Pipeline
 February 2008 £240
DRAXIS Health Inc -Detailed Product Pipeline
 February 2008 £240
DOR BioPharma Inc -Detailed Product Pipeline
 February 2008 £240
Cytogenix Inc -Detailed Product Pipeline
 February 2008 £240
Cytokinetics Inc -Detailed Product Pipeline
 February 2008 £240
Cytos Biotechnology AG -Detailed Product Pipeline
 February 2008 £240
DENTSPLY International Inc -Detailed Product Pipeline
 February 2008 £240
Diamyd Medical AB -Detailed Product Pipeline
 February 2008 £240
Discovery Laboratories Inc -Detailed Product Pipeline
 February 2008 £240
Dynavax Technologies Corp -Detailed Product Pipeline
 February 2008 £240
EPIX Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Echo Therapeutics, Inc -Detailed Product Pipeline
 February 2008 £240
Eisai Co Ltd -Detailed Product Pipeline
 February 2008 £240
Dyax Corp -Detailed Product Pipeline
 February 2008 £240
Duska Therapeutics Inc -Detailed Product Pipeline
 February 2008 £240
Dnaprint Genomics Inc -Detailed Product Pipeline
 February 2008 £240
Dov Pharmaceutical Inc -Detailed Product Pipeline
 February 2008 £240
Dr Reddys Laboratories Ltd -Detailed Product Pipeline
 February 2008 £240
Dragon Pharmaceutical Inc -Detailed Product Pipeline
 February 2008 £240
GW Pharmaceuticals PLC -Detailed Product Pipeline
 February 2008 £240
GammaCan International Inc -Detailed Product Pipeline
 February 2008 £240
Idera Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Idenix Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Imagenetix Inc -Detailed Product Pipeline
 February 2008 £240
Imarx Therapeutics, Inc. -Detailed Product Pipeline
 February 2008 £240
Imclone Systems Inc -Detailed Product Pipeline
 February 2008 £240
ISTA Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
IMCOR Pharmaceutical Co. -Detailed Product Pipeline
 February 2008 £240
Hospira Inc -Detailed Product Pipeline
 February 2008 £240
Human Genome Sciences Inc -Detailed Product Pipeline
 February 2008 £240
ICAgen Inc -Detailed Product Pipeline
 February 2008 £240
IDM Pharma Inc -Detailed Product Pipeline
 February 2008 £240
Immtech Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
ImmunoGen Inc -Detailed Product Pipeline
 February 2008 £240
Inflazyme Pharmaceuticals Ltd. -Detailed Product Pipeline
 February 2008 £240
Infinity Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Inhibitex Inc -Detailed Product Pipeline
 February 2008 £240
Innovive Pharmaceuticals, Inc. -Detailed Product Pipeline
 February 2008 £240
Inovio Biomedical Corp -Detailed Product Pipeline
 February 2008 £240
Indevus Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Incyte Corporation -Detailed Product Pipeline
 February 2008 £240
Immunomedics Inc -Detailed Product Pipeline
 February 2008 £240
Impax Laboratories Inc -Detailed Product Pipeline
 February 2008 £240
InNexus Biotechnology Inc -Detailed Product Pipeline
 February 2008 £240
InSite Vision Incorporated -Detailed Product Pipeline
 February 2008 £240
Hologic Inc -Detailed Product Pipeline
 February 2008 £240
Hollis -Eden Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Genitope Corp -Detailed Product Pipeline
 February 2008 £240
Generex Biotechnology Corporation -Detailed Product Pipeline
 February 2008 £240
Sirtris Pharmaceuticals, Inc. -Detailed Product Pipeline
 February 2008 £240
Gentium S.p.A -Detailed Product Pipeline
 February 2008 £240
Genzyme Corporation -Detailed Product Pipeline
 February 2008 £240
Genentech Inc -Detailed Product Pipeline
 February 2008 £240
Genelabs Technologies Inc -Detailed Product Pipeline
 February 2008 £240
Gedeon Richter Ltd -Detailed Product Pipeline
 February 2008 £240
GelStat Corp -Detailed Product Pipeline
 February 2008 £240
GenVec Inc -Detailed Product Pipeline
 February 2008 £240
Genaera Corporation -Detailed Product Pipeline
 February 2008 £240
GeoPharma Inc -Detailed Product Pipeline
 February 2008 £240
GeoVax Labs Inc -Detailed Product Pipeline
 February 2008 £240
Helix BioMedix Inc -Detailed Product Pipeline
 February 2008 £240
Hemispherx Biopharma Inc -Detailed Product Pipeline
 February 2008 £240
Hemobiotech Inc -Detailed Product Pipeline
 February 2008 £240
Hi -Tech Pharmacal Co Inc -Detailed Product Pipeline
 February 2008 £240
Hana Biosciences Inc -Detailed Product Pipeline
 February 2008 £240
Halozyme Therapeutics Inc -Detailed Product Pipeline
 February 2008 £240
Geron Corporation -Detailed Product Pipeline
 February 2008 £240
Gilead Sciences Inc -Detailed Product Pipeline
 February 2008 £240
GlaxoSmithKline plc -Detailed Product Pipeline
 February 2008 £240
H.Lundbeck AS -Detailed Product Pipeline
 February 2008 £240
CytoDyn Inc -Detailed Product Pipeline
 February 2008 £240
CytRx Corporation -Detailed Product Pipeline
 February 2008 £240
BioForm Medical, Inc. -Detailed Product Pipeline
 February 2008 £240
BioDelivery Sciences International Inc -Detailed Product Pipeline
 February 2008 £240
BioMarin Pharmaceutical Inc -Detailed Product Pipeline
 February 2008 £240
BioMimetic Therapeutics Inc -Detailed Product Pipeline
 February 2008 £240
BioSante Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
BioCryst Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Bio -Bridge Science Inc -Detailed Product Pipeline
 February 2008 £240
Beijing Med -Pharm Corp. -Detailed Product Pipeline
 February 2008 £240
Benda Pharmaceutical, Inc -Detailed Product Pipeline
 February 2008 £240
Benitec Ltd -Detailed Product Pipeline
 February 2008 £240
Bentley Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
BioSpecifics Technologies Corp -Detailed Product Pipeline
 February 2008 £240
BioSphere Medical Inc -Detailed Product Pipeline
 February 2008 £240
Biopure Corporation -Detailed Product Pipeline
 February 2008 £240
Biophage Pharma Inc -Detailed Product Pipeline
 February 2008 £240
Biosyntech Inc -Detailed Product Pipeline
 February 2008 £240
Biotech Holdings Ltd -Detailed Product Pipeline
 February 2008 £240
Biovail Corporation -Detailed Product Pipeline
 February 2008 £240
Bionovo Inc -Detailed Product Pipeline
 February 2008 £240
Bioniche Life Sciences Inc -Detailed Product Pipeline
 February 2008 £240
BioTime Inc -Detailed Product Pipeline
 February 2008 £240
Biocon Ltd -Detailed Product Pipeline
 February 2008 £240
Biodel Inc. -Detailed Product Pipeline
 February 2008 £240
Biogen Idec Inc -Detailed Product Pipeline
 February 2008 £240
Bayer Schering Pharma AG -Detailed Product Pipeline
 February 2008 £240
Bayer Ag -Detailed Product Pipeline
 February 2008 £240
Amicus Therapeutics, Inc. -Detailed Product Pipeline
 February 2008 £240
AXM Pharma Inc -Detailed Product Pipeline
 February 2008 £240
Anavex Life Sciences Corp. -Detailed Product Pipeline
 February 2008 £240
Arana Therapeutics Limited -Detailed Product Pipeline
 February 2008 £240
Ardea Biosciences, Inc. -Detailed Product Pipeline
 February 2008 £240
AVI BioPharma Inc -Detailed Product Pipeline
 February 2008 £240
AVAX TECHNOLOGIES INCORPORATED -Detailed Product Pipeline
 February 2008 £240
World Health Energy, Inc. -Detailed Product Pipeline
 February 2008 £240
3SBio Inc. -Detailed Product Pipeline
 February 2008 £240
AVANIR Pharmaceuticals -Detailed Product Pipeline
 February 2008 £240
AVANT Immunotherapeutics Inc -Detailed Product Pipeline
 February 2008 £240
AstraZeneca Plc -Detailed Product Pipeline
 February 2008 £240
Auxilium Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Barrier Therapeutics Inc -Detailed Product Pipeline
 February 2008 £240
Basilea Pharmaceutica AG -Detailed Product Pipeline
 February 2008 £240
Bavarian Nordic AS -Detailed Product Pipeline
 February 2008 £240
Baxter International Inc -Detailed Product Pipeline
 February 2008 £240
Barr Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Axcan Pharma Inc -Detailed Product Pipeline
 February 2008 £240
Avalon Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Avantogen Oncology, Inc. -Detailed Product Pipeline
 February 2008 £240
Avicena Group Inc -Detailed Product Pipeline
 February 2008 £240
Avigen Inc -Detailed Product Pipeline
 February 2008 £240
Biovest International Inc. -Detailed Product Pipeline
 February 2008 £240
Bradley Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
CollaGenex Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Cobalis Corp -Detailed Product Pipeline
 February 2008 £240
Columbia Laboratories Inc -Detailed Product Pipeline
 February 2008 £240
CombinatoRx Inc -Detailed Product Pipeline
 February 2008 £240
Compugen Ltd -Detailed Product Pipeline
 February 2008 £240
Clinuvel Pharmaceuticals Ltd -Detailed Product Pipeline
 February 2008 £240
Clinical Data Inc -Detailed Product Pipeline
 February 2008 £240
Chemgenex Pharmaceuticals Ltd -Detailed Product Pipeline
 February 2008 £240
Chemokine Therapeutics Corp -Detailed Product Pipeline
 February 2008 £240
Chugai Pharmaceutical Co Ltd -Detailed Product Pipeline
 February 2008 £240
Cleveland Biolabs Inc -Detailed Product Pipeline
 February 2008 £240
Corcept Therapeutics Inc -Detailed Product Pipeline
 February 2008 £240
Cortex Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Cyanotech Corporation -Detailed Product Pipeline
 February 2008 £240
Cyclacel Pharmaceuticals, Inc. -Detailed Product Pipeline
 February 2008 £240
Cyplasin Biomedical Ltd. -Detailed Product Pipeline
 February 2008 £240
Cypress Bioscience Incorporated -Detailed Product Pipeline
 February 2008 £240
Curis Inc -Detailed Product Pipeline
 February 2008 £240
CuraGen Corp -Detailed Product Pipeline
 February 2008 £240
Cougar Biotechnology, Inc. -Detailed Product Pipeline
 February 2008 £240
Critical Therapeutics Inc -Detailed Product Pipeline
 February 2008 £240
Crucell N V -Detailed Product Pipeline
 February 2008 £240
Cubist Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Chelsea Therapeutics International Ltd -Detailed Product Pipeline
 February 2008 £240
Chattem Inc -Detailed Product Pipeline
 February 2008 £240
Caraco Pharmaceutical Laboratories Ltd -Detailed Product Pipeline
 February 2008 £240
Callisto Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
CardioVascular BioTherapeutics Inc -Detailed Product Pipeline
 February 2008 £240
Cardiome Pharma Corp -Detailed Product Pipeline
 February 2008 £240
Cardium Therapeutics Inc -Detailed Product Pipeline
 February 2008 £240
Cadence Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
CYTOGEN Corporation -Detailed Product Pipeline
 February 2008 £240
Brainstorm Cell Therapeutics Inc -Detailed Product Pipeline
 February 2008 £240
Bristol -Myers Squibb Company -Detailed Product Pipeline
 February 2008 £240
CEL -SCI Corporation -Detailed Product Pipeline
 February 2008 £240
CV Therapeutics Inc -Detailed Product Pipeline
 February 2008 £240
Carribbean American Health Resorts Inc -Detailed Product Pipeline
 February 2008 £240
Carrington Laboratories Inc -Detailed Product Pipeline
 February 2008 £240
Celsion Corp -Detailed Product Pipeline
 February 2008 £240
Cephalon Inc -Detailed Product Pipeline
 February 2008 £240
Ceragenix Phamaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Cerus Corporation -Detailed Product Pipeline
 February 2008 £240
Cellegy Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Cell Therapeutics Inc -Detailed Product Pipeline
 February 2008 £240
Catalyst Pharmaceutical Partners Inc. -Detailed Product Pipeline
 February 2008 £240
CeNeS Pharmaceuticals Plc -Detailed Product Pipeline
 February 2008 £240
Celgene Corporation -Detailed Product Pipeline
 February 2008 £240
Cell Genesys Inc -Detailed Product Pipeline
 February 2008 £240
Insmed Incorporated -Detailed Product Pipeline
 February 2008 £240
Genta Incorporated -Detailed Product Pipeline
 February 2008 £240
Inspire Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Par Pharmaceutical Companies Inc -Detailed Product Pipeline
 February 2008 £240
Peplin Ltd -Detailed Product Pipeline
 February 2008 £240
Peregrine Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Perrigo Company -Detailed Product Pipeline
 February 2008 £240
Panacos Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Palatin Technologies Inc -Detailed Product Pipeline
 February 2008 £240
PDL BioPharma Inc -Detailed Product Pipeline
 February 2008 £240
POZEN Inc -Detailed Product Pipeline
 February 2008 £240
PacificHealth Laboratories Inc -Detailed Product Pipeline
 February 2008 £240
Pain Therapeutics Inc -Detailed Product Pipeline
 February 2008 £240
Pfizer Inc -Detailed Product Pipeline
 February 2008 £240
Pharmacopeia, Inc. -Detailed Product Pipeline
 February 2008 £240
Phytopharm PLC -Detailed Product Pipeline
 February 2008 £240
Phosphagenics Ltd. -Detailed Product Pipeline
 February 2008 £240
Pilot Therapeutics Holdings Inc -Detailed Product Pipeline
 February 2008 £240
Pipex Pharmaceuticals, Inc. -Detailed Product Pipeline
 February 2008 £240
Pluristem Therapeutics, Inc. -Detailed Product Pipeline
 February 2008 £240
Pharmos Corporation -Detailed Product Pipeline
 February 2008 £240
Pharmion Corp -Detailed Product Pipeline
 February 2008 £240
Pharmacyclics Inc -Detailed Product Pipeline
 February 2008 £240
Pharmasset, Inc. -Detailed Product Pipeline
 February 2008 £240
Pharmaxis Ltd. -Detailed Product Pipeline
 February 2008 £240
Pharming Group N.V. -Detailed Product Pipeline
 February 2008 £240
Osteologix, Inc. -Detailed Product Pipeline
 February 2008 £240
Osiris Therapeutics Inc -Detailed Product Pipeline
 February 2008 £240
Oculus Innovative Sciences Inc -Detailed Product Pipeline
 February 2008 £240
OXiGENE INC -Detailed Product Pipeline
 February 2008 £240
Omrix Biopharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
OncoVista, Inc. -Detailed Product Pipeline
 February 2008 £240
Oncolytics Biotech Inc -Detailed Product Pipeline
 February 2008 £240
OXIS International Inc -Detailed Product Pipeline
 February 2008 £240
OSI Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Nutrition 21 Inc -Detailed Product Pipeline
 February 2008 £240
Nuvelo Inc. -Detailed Product Pipeline
 February 2008 £240
Nventa Biopharmaceuticals Corp -Detailed Product Pipeline
 February 2008 £240
Nymox Pharmaceutical Corporation -Detailed Product Pipeline
 February 2008 £240
Oncothyreon, Inc. -Detailed Product Pipeline
 February 2008 £240
Onyx Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Orexigen Therapeutics, Inc. -Detailed Product Pipeline
 February 2008 £240
OrthoLogic Corporation -Detailed Product Pipeline
 February 2008 £240
Orthovita Inc -Detailed Product Pipeline
 February 2008 £240
Oscient Pharmaceuticals Corp -Detailed Product Pipeline
 February 2008 £240
Orchid Chemicals & Pharmaceuticals Ltd -Detailed Product Pipeline
 February 2008 £240
Oramed Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Opexa Therapeutics Inc -Detailed Product Pipeline
 February 2008 £240
Opko Health, Inc. -Detailed Product Pipeline
 February 2008 £240
Optimer Pharmaceuticals, Inc. -Detailed Product Pipeline
 February 2008 £240
Oragenics Inc -Detailed Product Pipeline
 February 2008 £240
Point Therapeutics Inc -Detailed Product Pipeline
 February 2008 £240
Polydex Pharmaceuticals Ltd -Detailed Product Pipeline
 February 2008 £240
Sanguine Corp -Detailed Product Pipeline
 February 2008 £240
Sangamo BioSciences Inc -Detailed Product Pipeline
 February 2008 £240
Sanofi -Aventis -Detailed Product Pipeline
 February 2008 £240
Santarus Inc -Detailed Product Pipeline
 February 2008 £240
Savient Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Samaritan Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Salix Pharmaceuticals Ltd -Detailed Product Pipeline
 February 2008 £240
Roche Holdings Ltd -Detailed Product Pipeline
 February 2008 £240
SCOLR Pharma Inc -Detailed Product Pipeline
 February 2008 £240
SGX Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
SIGA Technologies Inc -Detailed Product Pipeline
 February 2008 £240
Schering -Plough Corp -Detailed Product Pipeline
 February 2008 £240
Schwarz Pharma Ag -Detailed Product Pipeline
 February 2008 £240
Simcere Pharmaceutical Group. -Detailed Product Pipeline
 February 2008 £240
Sinobiomed Inc. -Detailed Product Pipeline
 February 2008 £240
Sinofresh Healthcare Inc -Detailed Product Pipeline
 February 2008 £240
Sinovac Biotech Ltd -Detailed Product Pipeline
 February 2008 £240
Shire plc -Detailed Product Pipeline
 February 2008 £240
Sepracor Inc -Detailed Product Pipeline
 February 2008 £240
SciClone Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Sciele Pharma, Inc. -Detailed Product Pipeline
 February 2008 £240
Seattle Genetics Inc -Detailed Product Pipeline
 February 2008 £240
Senetek Plc -Detailed Product Pipeline
 February 2008 £240
Rigel Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Rexahn Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Progenics Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Progen Pharmaceuticals Ltd. -Detailed Product Pipeline
 February 2008 £240
Protalex Inc -Detailed Product Pipeline
 February 2008 £240
Protalix BioTherapeutics, Inc. -Detailed Product Pipeline
 February 2008 £240
Proteo Inc -Detailed Product Pipeline
 February 2008 £240
Procyon Corp. -Detailed Product Pipeline
 February 2008 £240
Procter & Gamble Company -Detailed Product Pipeline
 February 2008 £240
Poniard Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Prana Biotechnology Ltd -Detailed Product Pipeline
 February 2008 £240
Prescient NeuroPharma Inc -Detailed Product Pipeline
 February 2008 £240
Pro -Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Protherics PLC -Detailed Product Pipeline
 February 2008 £240
Provectus Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Regeneron Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Renovis Inc -Detailed Product Pipeline
 February 2008 £240
Repligen Corporation -Detailed Product Pipeline
 February 2008 £240
Repros Therapeutics Inc -Detailed Product Pipeline
 February 2008 £240
RegeneRx Biopharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Regen Therapeutics plc -Detailed Product Pipeline
 February 2008 £240
Psivida Ltd -Detailed Product Pipeline
 February 2008 £240
QLT Inc -Detailed Product Pipeline
 February 2008 £240
Questcor Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Raptor Pharmaceuticals Corp. -Detailed Product Pipeline
 February 2008 £240
Nutra Pharma Corp -Detailed Product Pipeline
 February 2008 £240
Penwest Pharmaceuticals Co -Detailed Product Pipeline
 February 2008 £240
Maxygen Inc -Detailed Product Pipeline
 February 2008 £240
Matrixx Initiatives Inc -Detailed Product Pipeline
 February 2008 £240
Med Gen Inc -Detailed Product Pipeline
 February 2008 £240
Medarex Inc -Detailed Product Pipeline
 February 2008 £240
MediciNova Inc -Detailed Product Pipeline
 February 2008 £240
Marshall Edwards Inc -Detailed Product Pipeline
 February 2008 £240
Mannatech Inc -Detailed Product Pipeline
 February 2008 £240
MGI Pharma Inc -Detailed Product Pipeline
 February 2008 £240
Lpath Inc -Detailed Product Pipeline
 February 2008 £240
MacroChem Corporation -Detailed Product Pipeline
 February 2008 £240
Manhattan Pharmaceuticals Inc. -Detailed Product Pipeline
 February 2008 £240
MannKind Corp -Detailed Product Pipeline
 February 2008 £240
Medicis Pharmaceutical Corp -Detailed Product Pipeline
 February 2008 £240
Medicure Inc -Detailed Product Pipeline
 February 2008 £240
MicroIslet, Inc. -Detailed Product Pipeline
 February 2008 £240
MethylGene Inc -Detailed Product Pipeline
 February 2008 £240
Micromet Inc -Detailed Product Pipeline
 February 2008 £240
MiddleBrook Pharmaceuticals, Inc. -Detailed Product Pipeline
 February 2008 £240
Migenix Inc -Detailed Product Pipeline
 February 2008 £240
Metabolic Pharmaceuticals Ltd. -Detailed Product Pipeline
 February 2008 £240
Metabasis Therapeutics Inc -Detailed Product Pipeline
 February 2008 £240
Meldex International Plc -Detailed Product Pipeline
 February 2008 £240
Medivation Inc -Detailed Product Pipeline
 February 2008 £240
Memory Pharmaceuticals Corp -Detailed Product Pipeline
 February 2008 £240
Mentor Corporation -Detailed Product Pipeline
 February 2008 £240
Merck & Co Inc -Detailed Product Pipeline
 February 2008 £240
Lotus Pharmaceuticals, Inc. -Detailed Product Pipeline
 February 2008 £240
Lorus Therapeutics Inc -Detailed Product Pipeline
 February 2008 £240
IsoRay Inc -Detailed Product Pipeline
 February 2008 £240
Isis Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Javelin Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Jazz Pharmaceuticals, Inc. -Detailed Product Pipeline
 February 2008 £240
Johnson & Johnson -Detailed Product Pipeline
 February 2008 £240
Iomai Corp -Detailed Product Pipeline
 February 2008 £240
Inyx Inc -Detailed Product Pipeline
 February 2008 £240
Intellect Neurosciences, Inc. -Detailed Product Pipeline
 February 2008 £240
IntelGenx Technologies Corp. -Detailed Product Pipeline
 February 2008 £240
InterMune Inc -Detailed Product Pipeline
 February 2008 £240
Interpharm Holdings Inc -Detailed Product Pipeline
 February 2008 £240
Introgen Therapeutics Inc -Detailed Product Pipeline
 February 2008 £240
KV Pharmaceutical Co. -Detailed Product Pipeline
 February 2008 £240
Keryx Biopharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Lescarden Inc -Detailed Product Pipeline
 February 2008 £240
Lee Pharmaceuticals -Detailed Product Pipeline
 February 2008 £240
Lev Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Lexicon Pharmaceuticals, Inc -Detailed Product Pipeline
 February 2008 £240
Ligand Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Lannett Co Inc -Detailed Product Pipeline
 February 2008 £240
Labopharm Inc -Detailed Product Pipeline
 February 2008 £240
King Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Kosan Biosciences Incorporated -Detailed Product Pipeline
 February 2008 £240
Kyto BioPharma Inc -Detailed Product Pipeline
 February 2008 £240
LAM Pharmaceutical Corp -Detailed Product Pipeline
 February 2008 £240
Millennium Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
La Jolla Pharmaceutical Co -Detailed Product Pipeline
 February 2008 £240
Nitromed Inc -Detailed Product Pipeline
 February 2008 £240
North American Scientific Inc -Detailed Product Pipeline
 February 2008 £240
Northfield Laboratories Inc -Detailed Product Pipeline
 February 2008 £240
Northwest Biotherapeutics Inc -Detailed Product Pipeline
 February 2008 £240
Nile Therapeutics, Inc -Detailed Product Pipeline
 February 2008 £240
Neurologix Inc -Detailed Product Pipeline
 February 2008 £240
Neurogen Corporation -Detailed Product Pipeline
 February 2008 £240
Neurogenesis Inc -Detailed Product Pipeline
 February 2008 £240
NeurogesX, Inc. -Detailed Product Pipeline
 February 2008 £240
Novacea Inc -Detailed Product Pipeline
 February 2008 £240
Novadel Pharma Inc -Detailed Product Pipeline
 February 2008 £240
Novogen Ltd -Detailed Product Pipeline
 February 2008 £240
Novozymes A -Detailed Product Pipeline
 February 2008 £240
Nucryst Pharmaceuticals Corp -Detailed Product Pipeline
 February 2008 £240
Novo -Nordisk A -Detailed Product Pipeline
 February 2008 £240
Noven Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Novartis AG -Detailed Product Pipeline
 February 2008 £240
Novavax Inc -Detailed Product Pipeline
 February 2008 £240
Novelos Therapeutics Inc -Detailed Product Pipeline
 February 2008 £240
Neurocrine Biosciences Inc -Detailed Product Pipeline
 February 2008 £240
NexMed Inc -Detailed Product Pipeline
 February 2008 £240
Myriad Genetics Inc -Detailed Product Pipeline
 February 2008 £240
Mymetics Corporation -Detailed Product Pipeline
 February 2008 £240
NPS Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Nabi Biopharmaceuticals -Detailed Product Pipeline
 February 2008 £240
NanoViricides, Inc. -Detailed Product Pipeline
 February 2008 £240
Mylan, Inc. -Detailed Product Pipeline
 February 2008 £240
Neurochem Inc -Detailed Product Pipeline
 February 2008 £240
Miravant Medical Technologies -Detailed Product Pipeline
 February 2008 £240
Minrad International Inc -Detailed Product Pipeline
 February 2008 £240
Modigene, Inc. -Detailed Product Pipeline
 February 2008 £240
Molecular Insight Pharmaceuticals, Inc. -Detailed Product Pipeline
 February 2008 £240
Momenta Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
Nastech Pharmaceutical Co Inc -Detailed Product Pipeline
 February 2008 £240
MultiCell Technologies Inc -Detailed Product Pipeline
 February 2008 £240
Neuro -Hitech Pharmaceuticals Inc -Detailed Product Pipeline
 February 2008 £240
NeoPharm Inc -Detailed Product Pipeline
 February 2008 £240
Neurobiological Technologies Inc -Detailed Product Pipeline
 February 2008 £240
NatureWell Inc -Detailed Product Pipeline
 February 2008 £240
Nektar Therapeutics -Detailed Product Pipeline
 February 2008 £240
Neose Technologies Inc -Detailed Product Pipeline
 February 2008 £240
Drug-Drug Interactions
 February 2008 £115
MicroRNA Research Tools 2008
 January 2008 £1540
Molecular Imaging in Drug R&D and Medical Practice
Technologies, Applications, Markets
 January 2008 £715
Clinical Trails in India
 January 2008 £600
Home Medical Testing Devices
 January 2008 £1270
Preformulation Solid Dosage Form Development
Series: Drugs and the Pharmaceutical Sciences,
 January 2008 £130
Dircetory of Clinical Research Companies in India
 January 2008 £600
next-Generation Immunoassays
A Market and Technical Analysis of Research Applications 2007
 December 2007 £2300
Booming Clinical Trials Market in India
 November 2007 £765
Pharma R&D Fact Book, The
2006
 November 2007 £495
Clinical Data management in India
 November 2007 £600
Commercial and Pipeline Insight: Hepatitis B
 October 2007 £7600
Translational Medicine In Biopharmaceutical R&d
Enabling R&d Optimization And Early Detection Of Potential Failures
 October 2007 £1495
Cell-Based Assay Trends 2007
 October 2007 £1540
Strategies and Solutions for Publication Planning and Execution Excellence
 September 2007 £75
G-Protein Coupled Receptors (GPCRs) 2007
 September 2007 £2350
Commercial & Pipeline Insight: Hospital Antibacterials A market beyond MRSA
 August 2007 £8010
Commercial Insight: Antidiabetics Patent expiries and cost containment initiatives balanced by pipeline products
 August 2007 £8010
Pipeline Insight: Heart failure Week pipeline dominated by new indications and add-on diuretics
 August 2007 £6000
Incremental Improvements And Paradigm Shifts In Strategy Are Both Necessary To Boost Productivity
R&D Strategies
 August 2007 £7600
Pipeline And Commercial Insight
Pediatric And Adolescent Vaccines
 July 2007 £8000
Pharmaceutical and Medical Device Validation by Experimental Design
 July 2007 £95
RNA Interference for Drug R&D
Applications, Alliances, Companies and WW Market to 2011
 July 2007 £1650
Industry Insight Clinical Trials in India 2007
 May 2007 £400
Uniting R&D and Marketing for Integrated Early-Stage Market Preparation
 May 2007 £2095
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008
 May 2007 £270
The Emerging Markets of Clinical Research
 May 2007 £320
Outsourcing Clinical Trials
A Global Analytical Guide and Comparative Analysis of International Destinations, with Location Attractiveness Index
 May 2007 £1910
State of the Clinical Trials Industry 2007
 May 2007 £380
Innovations and Trends in Clinical Trials
Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology
 March 2007 £1430
Indication Expansion
Opportunities for successful lifecycle management
 March 2007 £1495
Translational Medicine - Drug Development Transformed? (Market Focus)
Drug Development Transformed? (Market Focus)
 February 2007 £947
Comprehensive Analysis of R&D and Commercialization
for Related Biotechnologies from Non-Biotechnology/Non-Pharmaceutical Companies 100
 February 2007 £695
Next Generation Protein Engineering and Drug Design
Strategies to boost efficacy and improve drug delivery
 February 2007 £1495
CRO Directory
India
 January 2007 £400
How Drugs Are Developed
3rd Edition
 January 2007 £1095
Mastering Phase IV Clinical Trials
 January 2007 £2800
Automated Biobanking Trends 2006
 December 2006 £1540
GPCR Screening & Profiling Trends 2006
 November 2006 £1540
Independent Clinical Laboratores
Sector Snapshot
 October 2006 £320
Winning R&D Productivity Strategies
Exploiting innovation, licensing and outsourcing opportunities
 October 2006 £1495
Reporting Adverse Events
 September 2006 £75
Research and Development in the Chemical and Pharmaceutical Industry
 August 2006 £55
Clinical Trials Business; The
 August 2006 £3085
Accelerating Patient Recruitment in Clinical Trials
 July 2006 £75
From blockbuster to nichebuster
Niche therapies drive future drugs growth and incentivize R&D investment over sales spending
 July 2006 £1055
Clinical Immunoanalyzer Markets
 June 2006 £4330
Clinical Chemistry Analyzers
 June 2006 £4330
Market for Antibodies; The
Keys to Success for Commercial Suppliers
 June 2006 £2165
New Drug Futures: Cancer Chapter
 May 2006 £695
New Drug Futures: Anti-Infective Chapter
 May 2006 £695
New Drug Futures
 May 2006 £2995
New Drug Futures: Central Nervous System Chapter
 May 2006 £695
New Drug Futures: Alimentary/Metabolic Chapter
 May 2006 £695
New Drug Futures: Cardiovascular Chapter
 May 2006 £695
New Drug Futures: Musculoskeletal Chapter
 May 2006 £695
New Drug Futures: Vaccines Chapter
 May 2006 £695
New Drug Futures: Respiratory Chapter
 May 2006 £695
Commercial Opportunities from Biomarkers
Transforming drug discovery, clinical development and molecular diagnostic
 May 2006 £1495
Clinical Pharmacokinetics
1st Edition
 March 2006 £29.95
The Impact of the Phase III Pipeline
Future Projections and Market Disruptions
 March 2006 £2230
Expediting Drugs and Biologics Development
A Strategic Approach 2006
 February 2006 £92
Clinical Trials Market 2006, The
 February 2006 £1499
Market for Restriction Enzymes; The
Cutting Out Your Competition
 February 2006 £3435
Scrip R&D Databook 2006
 January 2006 £1295
Survey of Private Companies Active in Pain Drug R&D; A
 January 2006 £415
Advertising to Life Scientists: Maximizing Ad Effectiveness
Maximizing Ad Effectiveness
 January 2006 £3435
Pharmaceutical Metrics
Measuring and Improving R&D Performance
 January 2006 £75
Clinical Trials Risk Management
 November 2005 £99
Global GCP Compliance Report, The
US, EU, and Japan
 October 2005 £35
Global R&D Spend 2002-2004
 October 2005 £470
Clinical Trials of Drugs and Biopharmaceuticals
 September 2005 £99
Clarke's Analysis of Drugs & Poisons - Book & CD-ROM Package
3rd Edition
 June 2005 £495
Clarke's Analysis of Drugs & Poisons - CD-ROM
3rd Edition
 June 2005 £350
UK Laboratory Equipment Market Development Report
 March 2005 £550
WorldCare Clinical: A Boutique Imaging CRO
 February 2005 £445
Orphan Drugs to 2008
Understanding regulation & market opportunity in Europe
 January 2005 £995
Key Trends to Watch in Contract Research for 2005
 January 2005 £280
Drug Products for Clinical Trials
An International Guide to Formulation-Production-Quality Control
 October 2004 £105
Bioinformatics Opportunities
Business models, trends and future challenges
 May 2004 £2500
Clinical Studies Management
 January 2004 £75
Clarke's Analysis of Drugs & Poisons
3rd Edition
 December 2003 £350
Pharmacogenomics: The Search for Individualized Therapies
 April 2002 £65